

AGC Biologics increases manufacturing capacity at Denmark

07 September 2018 | News

The addition of this proprietary bioreactor configuration will enable more flexible, innovative, and customized cGMP production capabilities, offering scales from 2000 L to 12000 L within a single run



AGC Biologics, a contract development and manufacturing organization specializing in the clinical and commercial manufacture of therapeutic proteins, announced that the company is increasing manufacturing capacity at its Copenhagen, Denmark facility as part of its global expansion strategy.

The Copenhagen facility will add a single-use bioreactor 6Pack suite consisting of six 2000-L production bioreactors and a 2000-L seed train. The six bioreactors will be run in single unit operations or in groups simultaneously, sequentially, or staggered to meet each client's specific production needs.

According to the company, the addition of this proprietary bioreactor configuration will enable more flexible, innovative, and customized cGMP production capabilities, offering scales from 2000 L to 12000 L within a single run.

The expansion also includes additional capabilities for harvesting, purification, buffer, and media production that will support the processing of different therapeutic proteins, including high antibody titer processes.

The company reports that the new suites are scheduled to be online in November 2018 and are expected to support the manufacturing of several commercial products.